ABVX

73.2009.24%
TA

Troy A. Ignelzi

Independent Director

Mr. Troy A. Ignelzi serves as Chief Financial Officer at Rapport Therapeutics, Inc. since November 1, 2023. He joined the firm on November 1, 2023. He serves as Executive Advisor of Private Equity at Sofinnova Investment, Inc. since March 12, 2024, where he is advising the firm's portfolio companies on corporate and financial strategy. He joined the firm on March 12, 2024. Mr. Ignelzi serves as Independent Director at Harmony Biosciences Holdings, Inc. since April 2026, as Independent Director at Contineum Therapeutics, Inc. since May 20, 2024, as Independent Director at ABIVAX Société Anonyme since July 2023, and as a Director of the Arizona BioIndustry Association. His prior experience includes serving as Independent Chair at Vedanta Biosciences, Inc. from July 2023 to February 2026, and as Independent Director from November 2020 to July 2023. He served as Chief Financial Officer and Secretary at Karuna Therapeutics, Inc. from March 5, 2019 to August 2023; he was employed at the company from March 2019 to September 2023. During his tenure at Karuna Therapeutics, he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings. Mr. Ignelzi served as Independent Director at CinCor Pharma, Inc. from May 2021 to February 2023, where he advised on the company’s sale to AstraZeneca. He served as Chief Financial Officer and Principal Accounting Officer at scPharmaceuticals Inc. from March 28, 2016 to February 28, 2019, and also provided consulting services to the company from February 2016 to March 2016. He served as Senior Vice President of Finance & Operations at Juventas Therapeutics, Inc. from October 2014 to February 2016 and as Senior Vice President of Operations & Business Development at Pharmalex GmbH from October 2013 to October 2014. At Esperion Therapeutics, Inc., he served as Vice President of Finance and as Vice President of Business Development from January 2009 to September 2013, and also served as Executive Director of Finance & Business Development. He served as Vice President of Business Development & Strategic Alliances at Insys Therapeutics, Inc. from February 2007 to February 2009. He served as Vice President of Emerging Technologies of the Greater Phoenix Economic Council since August 2005. He served as a specialty senior sales Representative at Eli Lilly and Company from February 2002 to August 2005. Mr. Ignelzi also served as Senior Vice President of Business Development at YES Pharmaceuticals, where he was responsible for financing engagements and provided strategic guidance to a number of clients' SEC filings and subsequent successful IPOs. Mr. Ignelzi has several years' experience in financial leadership, operations, and business development with start-up and established life sciences companies in the biotech and pharmaceuticals sectors. He has held executive management positions where he transitioned organizations from early stage start-up through mid-stage publicly traded companies. He focuses on providing financial and business development counsel. He holds a B.S. in Accounting from Ferris State University.

Positions